Hepatitis C : A brief clinical overview

ILAR Journal

Volumn 42, Issue 2, 2001, Pages 107-116

  Strader, Doris B ^a   Seeff, Leonard B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cirrhosis; Combination therapy; Fibrosis; genotype; Hepatitis C; Hepatocellular carcinoma; Interferon; Quasispecies

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

DISEASE COURSE; DRUG COMBINATION; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVER TUMOR; NEGRO; PATHOPHYSIOLOGY; PUBLIC HEALTH; REMISSION; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PUBLIC HEALTH; REMISSION, SPONTANEOUS; RIBAVIRIN;

EID: 0035222859     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.42.2.107     Document Type: Review

References (86)

1. AASLD [American Association for the Study of Liver Diseases]. 2001. AASLD Practices Guidelines: Diagnosis, management and treatment of hepatitis C (HCV) infection. Hepatology (In Press).
2. Ahmed A, Keeffe EB. 1999. Overview of interferon therapy for chronic hepatitis C. Clin Liver Dis 3:757-773.
3. Alter HJ. 1989. Chronic consequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, eds. Hepatology: Festschrift for Hyman J Zimmerman, MD. New York: Plenum Press, p 83-97.
4. Alter MJ. 1993. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 2:55-66.
5. Alter MJ. 1995a. Epidemiology of hepatitis C in the West. Semin Liver Dis 15:5-14.
6. Alter MJ. 1995b. Residual risk of transfusion-associated hepatitis. NIH Consensus Development Conference on Infectious Disease Testing for Blood Transfusions. Bethesda: NIH. p 23-27.
7. Alter MJ. 1997. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1:559-568.
8. Alter MJ. 1999. Epidemiology of hepatitis C in African Americans. (Abstract). Proceedings of the December 1999 NIH Conference on Hepatitis C in African Americans. p 24.
9. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562.
10. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeds EL, Beach MJ. 1992. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327:1899-1905.
11. Alter HJ, Purcell RH, Shin JW, Melpolder JC, Houghton M, Choo DL, Kuo G. 1989. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494-1500.
12. Alter HJ, Seeff LB. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liv Dis 20:17-35.
13. Atrah HI, Hutchinson F, Gough D, Ala FA, Ahmed MM. 1995. Hepatitis C virus seroconversion rate in established blood donors. J Med Virol 46:329-333.
14. Bartholomeusz A, Tomlinson E, Wright PJ, Birch C, Locarcini S, Weingold H, Marcoccio S, Polan G. 1994. Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds. Antiviral Res 24:341-350.
15. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thong SN, Seeff LB. 1997. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 26:473-477.
16. Bukh J, Apgar CL, Engle R, Gouindarajan S, Hegerich PA, Tellier R, Wong DC, Elkins R, Kew MC. 1998. Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: Genetic analysis of the virus and generation of a standardized challenge pool. J Infect Dis 178:1193-1197.
17. Bukh J, Miller RH, Purcell RH. 1995. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 15:41-63.
18. Bukh J, Purcell RH, Miller RH. 1993. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A 90:8234-8238.
19. Bukh J, Purcell RH, Miller RH. 1994. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A 91:8239-8243.
20. Conrad EU, Gretch DR, Obermeyer KR, Moogk MS, Sayers M, Wilson JJ, Strong DM. 1995. Transmission of the hepatitis C virus by tissue transplantation. J Bone Joint Surg 77:214-224.
21. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson M, Payne J, Dienstag JL, Van Thiel DH, Tamborro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitits Interventional Therapy Group. 1989. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506.
22. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Crax A, Ling MH, Albrecht J. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499.
23. De Francesco R, Pessi A, Steinkuhler C. 1998. The hepatitis C virus NS3 proteinase: Structure and function of a zinc-containing serine proteinase. In: Schinazi RF, Sommadossi J-P, Thomas HC, eds. Therapies for Viral Hepatitis. London: International Medical Press, p 225.
24. DiBiscegli AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. 2000. Iron reduction as adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 32:135-138.
25. DiBisceglie A, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. 1991. Long-term clinical and histologic follow up of chronic posttransfusion hepatitis. Hepatology 14:969-974.
26. Dienstag JL. 1983. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 85:439-462.
27. Domingo E, Holland J, Biebricher C, et al. 1994. Quasispecies: The concept and the world. In: Gibbs A, Calisher C, Garcia-Arenal F, eds. Molecular Evolution of Viruses. Cambridge: Cambridge University Press, p 181.
28. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and sindbis viruses. J Virol 68:6147-6160.
29. Eigen M. 1996. On the nature of virus quasispecies. Trends Microbiol 4:216-218.
30. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. 1998. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA 280:1569-1575.
31. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Maromo F, Sato C. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virs 1b: Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224-230.
32. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balistrieri A, Purcell RH, Alter HJ. 2000. The outcome of acute hepatitis C predicted by the evolution of viral quasispecies. Science 288:339-344.
33. Farci P, Shimoda A, Wong D, Cabezon T, DeGioannis D, Strazzera A, Shimizo Y, Shapiro M, Albrecht J, Purcell RH. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93:15394-15399.
34. Forns X, Bukh J. 1998. Methods for determining the hepatitis C virus geno-type. Viral Hepatitis Rev 4:1.
35. Forns X, Bukh J. 1999. The molecular biology of the hepatitis C virus: Genotypes and quasispecies. Clin Liver Dis 3:693-716.
36. Gilliam JH III, Geisinger DR, Richter JE. 1984. Primary hepatocellular carconima after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med 101:794.
37. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP. 2000. A dose-ranging study of pegylated interferon α-2b and ribavirin in chronic hepatitis C. The hepatitis C Intervention Therapy Group. Hepatology 32:647-653.
38. Gonzalez-Peralta RP, Qian K, She JY, Davis GI, Ohno T, Mizikami M, Lau JY. 1996. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 49:242-247.
39. Gretch DR. 1997. Use and interpretation of HCV diagnostic tests in the clinical setting. Clin Liver Dis 1:543-557.
40. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy RK, Albert DG, Witt K, Blat LM. 1998. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 27:1136-1142.
41. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SM, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680.
42. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M. Ohkoshi S, Shimotohno K. 1991. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 175:220-228.
43. Hijikata M, Mizushima H, Akagi T, Mon S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 67:4665-4675.
44. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi T, Kato N, Kimura K, Shimotohno K. 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci U S A 90:10773-10777.
45. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. 1994. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 20:1144-1151.
46. Hwang S-B, Lo S-Y, Ou J-H, et al. 1995. Detection of cellular proteins and viral core protein interacting with the 5′ untranslated region of hepatitis C virus RNA. J Biomed Sci 2:227.
47. Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kumura K, Shimotohno K. 1994. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun 205:320-326.
48. Kenny-Walsh E for the Irish Hepatology Research Group. 1999. Clinical outcomes after hepatitis infection from contaminated anti-globulin. N Engl J Med 340:1228-1233.
49. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Pepre CA, O'Malley ET, Harveson SL, Rice CM, Mureko MA, Caron PR, Thomson JA. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.
50. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter JH. 1990. Inter-relationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 12:671-675.
51. Koizumi K, Enomoto N, Kurosaki M, Murakumi T, Izomi N, Marumo F, Sato C. 1995. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22:30-35.
52. Lin CM, Lindenbach BD, Pragai BM, McCourt DW, Rice CM. 1994. Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini. J Virol 68:5063-5073.
53. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Haboka N, Mooman EW, Adachi T, Hostomska Z. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and structural zinc binding site. Cell 87:331-342.
54. Maertens G, Stuyver L. 1997. Genotypes and genetic variation of hepatitis C virus. In: Harrison TJ, Zuckerman A, eds. The Molecular Medicine of Viral Hepatitis (Medical Science Series). Chichester, England: John Wiley & Sons, p 183.
55. Major ME, Feinstone SM. 1997. The molecular virology of hepatitis C. Hepatology 25:1527-1538.
56. Makris BM, Garson CJ, Ring PW, et al. 1993. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 81:1898-1902.
57. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492.
58. McHutchinson JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J for the International Hepatitis Interventional Therapy Group. 2000. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 119:1317-1323.
59. Mizushima H, Hijikata M, Asabe S, Hirota M, Kumora K, Shimotohno K. 1994. Two hepatitis C virus glycoprotein E2 products with different C termini. J Virol 68:6215-6222.
60. Morishima C, Gretch DR. 1999. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Clin Liver Dis 3:717-740.
61. NIH [National Institutes of Health]. 1997. NIH Consensus Development Conference on the Management of Hepatitis C. Bethesda: NIH.
62. Ogata N, Alter HJ, Miller RH, Purcell RH. 1991. Nucleotide sequence and mutation rate for the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 88:3392-3396.
63. Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S. 1992. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624.
64. Okamoto H, Dojima M, Okada S-I, Yoshizawa H, Iizuka H, Tamaka T, Muchmore EE, Peterson DA, Ho Y, Mishiro S. 1992. Genetic drift of hepatitis C virus during a 8.2-year infection in a chimpanzee: Variability and stability. Virology 190:894-899.
65. Okamoto H, Kurai K, Okada S-I, Yamamoto K, Lizuka H, Tamaka T, Fukuda S, Tsuda F, Mishio S. 1992. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: Comparative study of four distinct genotypes. Virology 188:331-341.
66. Pereira BJ, Milford EL, Kirkman RL, Quan S, Sayne KR, Johnson PJ, Wilkes JC, Levey AS. 1992. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 327:910-915.
67. Pessoa MG, Wright TL. 1997. Hepatitis C infection in transplantation. Clin Liver Dis 1:663-690.
68. Polyak SJ, Faulkner G, Carithers RL, Corey L, Gretch DR. 1997. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: Correlation with response to interferon therapy. J Infect Dis 175:1101-1107.
69. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomized trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 353:1426-1432.
70. Ray RB, Lagging LM, Meyer K, Ray R. 1996. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 70:4438-4443.
71. Reed KE, Rice CM. 1998. Molecular characterization of hepatitis C virus. Curr Stud Hematol Blood Transfus 62:1.
72. Rice CM. 1996. Flaviviridae: The viruses and their replication. In: Fields BN, Knippe DM, Howley PM, eds: Fields Virology, ed 3. Philadelphia, Lippincott-Raven. p 931.
73. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. 1996. The risk of transfusion-transmitted viral infections. N Engl J Med 334:1685-1690.
74. Seeff LB. Hepatitis C from a needlestick injury. 1991. Ann Intern Med 115:411.
75. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason DK, Smoak BL, Johnson LD, Lee SR, Kaplan EL. 2000.45-year follow-up of hepatitis C infection in healthy young adults. Ann Intern Med 132:105-111.
76. Shiffman M, Pockros PJ, Reddy R, Wright TL, Reindollar R, Fried MW, Purdum PP III, Everson G, Pedder S. 1999. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2A (PEG) versus standard interferon alfa-2A (IFN) for treatment of chronic hepatitis C. (Abstract). Gastroenterology 116(Suppl):L0418.
77. Simmonds P, Holmes EC, Cha T-A, Chan SW, McOmish F, Irvine B, Beall E, Yapp PL, Kolberg J, Ordea MS. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 region. J Gen Virol 74:2391-2399.
78. Suzuki JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM, Collett MS. 1993. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with related pestivirus and flavivirus enzymes. J Virol 67:6152-6158.
79. Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, Jackson DR, April M, Barker LF, Pineda-Tainondong G. 1978. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1:463-466.
80. Tabor E, Purcell RH, Gerety FJ. 1981. Primate animal models and titered inocula for the study of human hepatitis A, B, and non-A, non-B hepatitis. J Med Primatol 1:305-318.
81. Tai C-L, Chi W-K, Chen D-S, Hwang LH. 1996. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 70:8477-8484.
82. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. 1999. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341:866-870.
83. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. 2000. Low frequency of cirrhosis in a hepatitis C genotype 1b single-source outbreak in Germany: A 20-year multicenter study. Hepatology 32:91-96.
84. Wiley TE, Brown JL, Chan J. 1999. The natural history of hepatitis C in African Americans. (Abstract). Proceedings of the December 1999 NIH Conference on Hepatitis C in African Americans. Bethesda: NIH. p 26-27.
85. Yanagi M, St. Claire M, Shapiro M, Emerson SU, Purcell RH, Bukh J. 1998. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244:161-172.
86. Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672.